RxDoctor Payments Data

Savitha Balakrishna, MD

Family Medicine · Lufkin, TXNPI 1215011747

Payments from drug & device makers

$948in general payments, 2019–2025

Across 45 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$224
  • AstraZeneca$185
  • Sanofi-aventis U.S. LLC$150
  • Boehringer Ingelheim$97
  • Novo Nordisk$78
  • Pfizer$41
  • plus $173 from 7 others

What the payments were for

  • Speaking & faculty fees$15016%
  • Food & beverage$79884%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$948 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$2,065
Medicare patients
20
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide33$38,773
FarxigaDapagliflozin Propanediol22$20,503
OzempicSemaglutide14$18,994
MounjaroTirzepatide14$13,948
JardianceEmpagliflozin16$10,827
LinzessLinaclotide16$10,827
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,129
MyrbetriqMirabegron13$8,252
SynthroidLevothyroxine Sodium20$1,255
Gabapentin88$1,249
Divalproex Sodium ErDivalproex Sodium12$1,098
Albuterol Sulfate HfaAlbuterol Sulfate43$1,090
Duloxetine Hcl32$1,063
Atorvastatin Calcium113$992
Levothyroxine Sodium93$991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$185$20,50322 claims
Novo NordiskOzempic$78$18,99414 claims
AbbVieLinzess, Synthroid$33$12,08136 claims
Boehringer IngelheimJardiance$97$10,82716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →